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Abstract
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults over 50 years old.
Genetic, epidemiological, and molecular studies are beginning to unravel the intricate mechanisms underlying this
complex disease, which implicate the lipid-cholesterol pathway in the pathophysiology of disease development
and progression. Many of the genetic and environmental risk factors associated with AMD are also associated with
other complex degenerative diseases of advanced age, including cardiovascular disease (CVD). In this review, we
present epidemiological findings associating AMD with a variety of lipid pathway genes, cardiovascular phenotypes,
and relevant environmental exposures. Despite a number of studies showing significant associations between AMD
and these lipid/cardiovascular factors, results have been mixed and as such the relationships among these factors
and AMD remain controversial. It is imperative that researchers not only tease out the various contributions of such
factors to AMD development but also the connections between AMD and CVD to develop optimal precision
medical care for aging adults.
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Background
Age-related macular degeneration (AMD) is a progres-
sive blinding disease with no cure at present. In its most
advanced stages, it deprives an individual of his or her
ability to perform basic activities such as reading, recog-
nizing faces, and driving. Approximately 11 million indi-
viduals are affected with AMD in the United States
(U.S.) alone, with a global prevalence of 170 million.
AMD is thereby the leading cause of visual disability in
the industrialized world and the third leading cause glo-
bally [1–3]. Aging is the greatest risk factor; therefore,
the prevalence of AMD in the U.S. is anticipated to in-
crease to 22 million by the year 2050, while the global
prevalence is expected to increase to 288 million by the
year 2040 [1, 2]. In the U.S., the prevalence of AMD is
similar to that of all invasive cancers combined and
more than double the prevalence of Alzheimer’s Disease
[1, 4]. This high prevalence leads to an annual $4.6
billion direct healthcare cost due to AMD in the U.S.
[5]. As the aging population increases, this expenditure
is likewise expected to increase proportionately.
AMD is a neurodegenerative disease that preferen-
tially affects the macular (central) region of the retina,
although the reason for this is not clearly understood.
The disease is categorized into early, intermediate, or
advanced stages based on the severity of symptoms, in-
cluding the number and size of drusen accompanied by
hyper- or hypopigmentary changes and the presence or
absence of choroidal neovascularization. The yellowish
lipid-rich, protein-containing drusen deposits accumu-
late between the retinal pigment epithelium (RPE) and
Bruch’s membrane and are symptomatic of early disease.
Drusen are considered the “hallmark” of AMD. The term
“dry AMD” refers broadly to early or intermediate stages
as well as a late stage referred to as geographic atrophy
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(GA). The advanced GA stage involves the loss of RPE and
choroid in at least the macular region of the retina, which
leads to a gradual loss of photoreceptors and central vision
[6–8]. The term “wet AMD” refers to the advanced neo-
vascular (or exudative) stage of the disease, which presents
a more rapid loss of vision relative to GA. Neovascular
AMD arises from the growth of abnormal blood vessels
from the choroid into the normally avascular sub-RPE and
sub-retinal regions [choroidal neovascularization (CNV)]
[8, 9]. Although neovascular AMD represents a small pro-
portion of total AMD cases, it accounts for the majority of
blindness associated with AMD [10].
Precise diagnosis and staging requires an ophthalmic
exam that includes fundus imaging of the retina for
visualization of symptoms such as drusen deposits, pig-
mentary changes in the RPE, RPE and neural retinal de-
generation and loss, and/or exudative changes in the
retina (Fig. 1) [8, 11–13]. Further imaging with fluorescein
angiography (which visualizes blood vessels) confirms the
presence or absence of CNV [11]. Additional imaging
techniques, such as optical coherence tomography (OCT),
can also be implemented to confirm diagnosis. With these
data, clinicians and researchers are able to categorize pro-
gression based on a standard grading scale, such as the
Fig. 1 Progression of age-related macular degeneration. a Schematic drawing of an eye with relevant anatomic labels. b Fundus images
of normal, intermediate (AREDS3), and advanced AMD (CNV and GA) eyes. Note the drusen deposits (AREDS3), atrophy (GA), and neovascularization
(CNV). AMD, age-related macular degeneration; CNV, choroidal neovascularization; GA, geographic atrophy. Photos taken from DeAngelis lab patient
cohorts. The study protocol was reviewed and approved by the Institutional Review Board at the University of Utah and conforms to the tenets of the
Declaration of Helsinki
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Age-Related Eye Disease Study (AREDS) system, in which
eyes are ranked on a scale of 1–4 [14, 15]. The AREDS
grading system denotes non-AMD eyes as category 1
(AREDS1). Category 2 (AREDS2) eyes include early AMD
cases in which symptoms were limited to small drusen
<63 μm (also referred to as “hard” drusen), a single
intermediate-sized druse 63–124 μm, and/or pigmentary
changes. Category 3 (AREDS3) eyes include those with
more extensive drusen such that they have at least one
large druse >124 μm (“soft” druse), multiple intermediate
drusen, and/or GA not involving the central macula. Cat-
egory 4 (AREDS4) refers to eyes exhibiting GA involving
the central macula and/or CNV. (See Khan et al. [16] for a
detailed review of drusen and drusen-like deposits).
Most current therapies are directed toward the more
advanced neovascular (“wet”) stage of AMD, target
established abnormal blood vessel growth through
antibody-based inhibition of vascular endothelial growth
factor A (VEGFA), and demonstrate a range of efficacy.
For a small subset of patients, these therapies result in
stable to improved visual acuity without the need for on-
going treatment [17, 18]. However, the majority of patients
require indefinite treatment or demonstrate progression
of disease despite therapies [18]. With 1 in 10 people
living in the U.S. aged 50+ years-old expected to be
diagnosed with AMD by 2050 [19], affected individ-
uals will continue to suffer and healthcare costs will
rise exponentially unless the disease can be prevented,
delayed, and/or treated effectively.
The development of new therapeutics, both for wet
and dry forms of the disease, has received much atten-
tion, with the goal that they may ultimately improve out-
comes and reduce the burden of treatment on affected
individuals (see clinicaltrials.gov for a list of current clin-
ical trials investigating a variety of potential therapeutics
for both wet and dry AMD) [20, 21]. Therapeutics that
can prevent the progression from early to intermediate
and/or from intermediate to advanced stages of the
disease are greatly needed to alleviate the profound
detrimental impacts of vision loss; elucidation of the
molecular mechanisms involved in the etiology and pro-
gression of AMD, taking into account evidence from
gene expression, epigenetic, molecular, and biochemical
studies to complement genetic epidemiological studies,
will be necessary to accomplish this goal [22–25].
Understanding the relationships among diseases that
may share overlapping pathophysiology and/or are co-
morbid pathologies with AMD could help to uncover
disease etiology in AMD. More importantly, because
multiple co-morbidities are common among the aging
population, understanding any commonalities in disease
pathology among these various conditions will also im-
prove the co-management of co-occurring conditions,
such as AMD co-occurring with cardiovascular disease
(CVD), allowing for synchronous preventative and/or
therapeutic approaches.
AMD is a complex disease with many genetic and
environmental factors, as well as interactions among
these many factors, which influence susceptibility to
risk [25–39]. Some of these epidemiological risk factors
for AMD can be modified, and include body-mass index
(BMI), smoking tobacco, diet, and blood lipid and choles-
terol levels [35]. However, other factors cannot be modi-
fied at present, including genotype at a given risk locus,
sex, ethnicity, and age.
AMD pathogenesis
How these genetic and environmental factors influence
the development and progression of disease remains
largely unknown. One model for the development of ad-
vanced neovascular AMD suggests that the accumulation
of drusen disrupts the connection between the RPE and
the choroidal blood supply, thereby inducing hypoxia. The
hypoxia in turn induces the expression of VEGFA and
other pro-angiogenic factors to promote the formation of
new vessels [40]. This model does not provide a complete
picture, however, as extensive data support roles for
local inflammation, complement activation, oxidative
stress, and lipid homeostasis in the pathogenesis of
AMD [24, 27, 41–45]. The accumulation of drusen
deposits has been proposed to result from aberrant
lipid influx into and efflux from the RPE [45, 46].
Likewise, drusen accumulation and composition ap-
pear to resemble atherosclerotic plaques [47]. Yet the
exact molecular causes of AMD pathogenesis remain
unclear. Although candidate gene, genome-wide asso-
ciation studies (GWAS), and epidemiological studies
have implicated the lipid metabolism-cholesterol path-
way in AMD pathophysiology, the role is unclear and
at times inconsistent [24, 48–53].
Drusen deposition and atherosclerotic plaque
formation
Drusen are the hallmark lesions of AMD. The size and
number of drusen deposits are generally indicative of
disease severity and risk for progression to advanced
disease [15, 54]. Studies investigating the composition of
drusen have provided insight into the pathways involved
in drusenogenesis and have illustrated commonalities
with other degenerative processes such as atherosclerotic
plaque formation (Table 1) [55]. Bruch’s membrane and
the RPE function similarly to the blood brain barrier,
with oxygen, lipids, and other nutrients passing between
the choroidal blood supply and the retina via the RPE.
As such, drusen lipid components appear to be sourced
primarily from the RPE and photoreceptors, with the
choroidal blood supply contributing a minor fraction,
while the drusen proteins appear to come from both
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choroidal cells and serum [55]. This is in contrast to the
fatty atherosclerotic plaque lesions in which the lipids,
proteins, and lipoproteins are sourced systemically, that is,
from the circulation [56]. Drusen and atherosclerotic pla-
ques also have a number of components in common,
which speaks to their common pathophysiologies, includ-
ing complement components [i.e., vitronectin (VTN) and
complement component 3 (C3)], amyloid (beta, P), apoli-
poproteins, esterified and unesterified cholesterol, matrix
metalloproteinase (MMPs), and calcium [55, 56].
Approximately 20 years ago, Dr. Friedman proposed the
“hemodynamic model” of AMD after observing similar-
ities between drusen and atherosclerotic plaques, which
he updated over the following decade [57–60]. In this
model, processes parallel to atherosclerotic plaque forma-
tion, leading from lipid deposition in the sclera and
Bruch’s membrane to CNV were outlined. Friedman’s
model hypothesized that the lipids deposited in the sclera
increase scleral stiffness and choroidal vascular resistance,
which decreases choroidal blood flow and increases chor-
iocapillary pressure, which leads to CNV. Concurrently,
lipid deposition in Bruch’s membrane leads to degener-
ation of elastin and collagen as well as basal deposits and
drusen. The elastin and collagen degeneration leads
to calcification, fracture, upregulation of VEGFA, and
ultimately CNV. In this hypothesis, the lipid accumu-
lation is the causative step leading to progression of
disease. However, the drusen deposits themselves are
proposed in this model to lead to RPE atrophy, but
not to CNV, and would therefore not be causative of
progression to neovascular disease.
Gelfand and Ambati recently published a “revised
hemodynamic theory of age-related macular degener-
ation”, adding to this vascular model [37]. They propose
that drusen selectively localize and accumulate as a result
of local hemodynamic parameters within the choriocapil-
laris, which then determines the severity and progression
of disease towards both GA and/or neovascular AMD.
Although they incorporate the involvement of other
processes, they posit that the hemodynamic factors are
the initial and driving forces in AMD development and
accumulation.
Additionally, a growing appreciation for the involvement
of chronic inflammation, endothelial dysfunction, and oxi-
dative stress in both AMD and atherosclerosis has shifted
the emphasis of these diseases away from being consid-
ered simply lipid-deposition diseases [47]. Tan et al. argue
in a recent review that immune system activation in AMD
results from pathologic lipid accumulation [36]. However,
Booij et al. contend that the accumulation of sub-retinal
deposits is a normal process of aging, which only becomes
pathogenic once the healthy involvement of the comple-
ment system becomes disrupted (likely through oxidative
damage), uncontrolled, and thereby contributes to cellular
damage and death [56]. Either way, the accumulation of
drusen deposits precedes the further progression of patho-
logical disease, although it has not been shown to be
causative of progression [61–63]. Similarly, atherosclerotic
Table 1 Representative characteristics of drusen deposits and atherosclerotic plaques
Disease parameter Drusen Plaques Reference/Reviewed in
Lipid deposits X X Curcio et al. 2011 [203], Vaya 2013 [204]
Endothelial dysfunction X X Machalinska et al. 2011 [205], Castellon & Bogdanova 2016 [206]
Complement activation X X McHarg et al. 2015 [207], Vlaicu et al. 2016 [208]
Oxidative stress X X FAnjul-Moles & Lopez-Riqelme 2016 [209], Vaya 2013 [204]
MMP involvement X X Lambert et al. 2002 [210], Galis & Khatri 2002 [211]
Hyperhomocysteinaemia X X Vine et al. 2005 [212]
Macrophage involvement X X Grunin et al. 2014 [213], Chistiakov et al. 2015 [214]
Smooth muscle cell involvement X Chistiakov et al. 2015 [215]
Decreased blood flow X X Berenberg et al. 2012 [216], Lowe 2003 [217]
VEGF upregulation/Progression
with neovascularization
X X Bhutto & Lutty 2012 [218], Moreno et al. 2012 [219]
Rupture X Badimon & Vilahur 2014 [220]
Spontaneous regression X Toy et al. 2013 [221]
Lipid source Local and circulating Circulating Booij et al. 2010 [56], Vaya 2013 [204]
Major deposit components
Amyloid X X Ohno-Matsui 2011 [222], Jans et al. 2006 [223]
Cholesterol/Cholesteryl esters X X Pikuleva & Curcio 2014 [45], Vaya 2013 [204]
Lipoproteins X X Curcio et al. 2011 [203], Linton et al. 2000 [224]
The “x” in columns 2 and 3 indicates that the parameter/component in the corresponding row is associated with/present in wither drusen (column 2) or
atherosclerotic plaques (column 3)
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plaques are thought to initiate from changes in the
arterial endothelial cell lining, which when combined
with dyslipidemia, hypertension, or pro-inflammatory
agents, promotes the accumulation of low density
lipoprotein- cholesterol (LDL-C) particles and further
immune involvement leading eventually to smooth
muscle migration, destabilization of the plaque, and
ultimately thrombosis [64].
Disease prevalence
The prevalence of AMD varies greatly by ethnicity with
non-Hispanic White Europeans having the greatest dis-
ease burden. In this review, we refer to race and ethnici-
ties as given by the authors of the original studies. We
make no attempt to standardize the designations as each
study has its own method for classifying participants.
A recent study by Wong et al. calculated pooled
prevalence of ethnically diverse population-based
studies of AMD (age range of 45–85 years) and con-
firmed that prevalence was greatest among those individ-
uals of European descent at 12.3–30% with increasing age
[2]. Disease burden, although slightly less, is still great
amongst Hispanics (10.4%), Africans (7.5%) and Asians
(7.4%) [2]. Still, others have estimated a lower disease
burden within the U.S., with non-Hispanic White Eu-
ropeans having the highest at almost 7.3% and Afri-
can-Americans at 2.4% [65]. Regardless, it is clear that the
prevalence of AMD varies by ethnicity and racial group,
and therefore the role of genetic variants, environmental
exposures, and their interplay in AMD susceptibility will
likely vary by ethnicity as well.
Genome-wide and candidate gene association
studies of AMD
The lipid metabolism-cholesterol pathway has long been
implicated in AMD, and emerged genetically in candi-
date gene and then GWAS studies [23, 50, 51, 66–68]. A
recent exome chip study by Fritsche et al. identified 34
loci representing both common and rare variants near
or around 860+ genes associated with AMD in individ-
uals mostly of European Caucasian ancestry (Table 2)
[24]. In addition to genes previously found at genome-
wide significance, this study identified lipid pathway
genes, including the ATP-binding cassette transporter A-
1 (ABCA1), ABCA7, apolipoprotein C2 (APOC2),
APOC4, and phospholipid transfer protein (PLTP); the
complement pathway VTN gene; and the angiogenesis-
associated matrix metalloproteinase-9 (MMP9) gene.
MMP9 was shown specifically to be associated with the
neovascular subtype and is the first gene to associate
with a single AMD subtype. A number of other lipid as-
sociated pathway genes were previously shown by
GWAS to associate with AMD, including genes encod-
ing apolipoprotein E (APOE), cholesteryl ester transfer
protein (CETP), and hepatic triglyceride lipase (LIPC)
[68]. In fact, many of these genes were shown via mo-
lecular or candidate gene studies to be associated with
AMD, including ABCA1, ABCA7, APOE, CETP, LIPC,
and MMP9 [48, 50, 51, 67, 69–77]. Several candidate
gene studies have also implicated disease involvement
for other lipid metabolism genes, such as RAR related
orphan receptor A (RORA), roundabout guidance recep-
tor 1(ROBO1), lipoprotein lipase (LPL), LDL receptor re-
lated protein 5 (LRP5), LRP6, very low density
lipoprotein receptor (VLDLR), fatty acid desaturase 1–3
(FADS1-3), and adiponectin receptor 1 (ADIPOR1), many
of which have been implicated in populations of various
ethnicities (including RORA and ROBO1) [49, 76–85].
(For further review, please see [45, 86]). The absence of
genome-wide significant associations for these candidate
genes may reflect the heterogeneous nature of AMD, the
diversity of the populations, and the need for more
rigorous and standardized phenotyping within the large,
multi-center cohorts required for genome-wide analyses.
One of the best characterized lipid-associated genes in
AMD, ABCA1 participates in cholesterol efflux out of
tissues and into high-density lipoprotein (HDL) particles,
catalyzing the rate limiting step of HDL particle
Table 2 Lipoprotein genes associated with AMD incidence and prevalence
Gene Gene product Chromosome Function Animal model Association with AMD
ABCA1 ATP binding cassette subfamily
A member 1
9q31.1 Cholesterol transport KO [93, 225], conditional
KO [94], transgenic [95]
Zareparsi et al. 2005 [69]
ABCA7 ATP binding cassette subfamily
A member 7
19p13.3 Lipid homeostasis KO [96] Logue et al. 2014 [48]
APOE Apolipoprotein E 19q13.2 Lipid catabolism transgenic [97], KO [98] Klaver et al. 1998 [67]
CETP Cholesteryl ester transfer protein 16q21 Lipid metabolism transgenic [99] Chen et al. 2010 [50]
LIPC Hepatic triglyceride lipase 15q21.3 Lipid metabolism KO [100] Chen et al. 2010 [50]
MMP9 Matrix metalloproteinase-9 20q13.12 ECM breakdown/angiogenesis KO [101] Hussain et al. 2011 [70]
PLTP Phospholipid transfer protein 20q13.12 Lipid transfer to HDL transgenic [102], KO [103] Fritsche et al. 2015 [24]
VTN Vitronectin 17q11 Cell adhesion/complement pathway No Fritsche et al. 2015 [24]
ECM = extracellular matrix; HDL = high-density lipoprotein; KO = knockout
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formation and opposing atherosclerotic processes [87].
Impaired cholesterol efflux resulting from loss of ABCA1
expression in older macrophages has recently been
shown by Sene et al. to associate with the promotion of
pathologic vascular proliferation in a mouse model of
AMD [88]. Reduction of ABCA1 expression was also ob-
served in peripheral blood mononuclear cells in aging
adult (67–87 years old) compared to young adult (25–34
years old) human donors [88]. DNA methylation at the
ABCA1 promoter has been shown to negatively correlate
with HDL levels and incidence of coronary artery disease
(CAD) in individuals with familial hypercholesterolemia,
and ABCA1 promoter methylation levels have been
shown to increase with age [89, 90]. The accumulation
of DNA methylation at the ABCA1 promoter with age
may account for the reduction of ABCA1 expression ob-
served by Sene et al. in older adults, which would poten-
tially contribute to both increased risk of AMD and
CAD in aging individuals. ABCA1 agonists have been
under study for their potential anti-atherogenic proper-
ties [91]. The work by Guay et al. and Sene et al. suggest
that manipulating the ABCA1 promoter methylation
levels may be an alternative approach for increasing or
restoring ABCA1 function and potentially reducing inci-
dences of both CAD and AMD.
In addition to differences in disease prevalence among
various ethnic and racial populations, recent work has
also shown variability in the genetic contributions to dis-
ease risk among populations. The Population Architec-
ture Using Genomics and Epidemiology (PAGE) study
demonstrated that AMD risk appears to differ with re-
spect to lipid metabolism and cholesterol-related genes
in Mexican Americans, Asian Americans, African Amer-
icans, and non-Hispanic White Europeans when all
types of AMD were examined [52]. In fact, in this study,
none of the major risk variants for AMD e.g., HtrA
serine peptidase 1 (HTRA1)/age-related maculopathy
susceptibility 2 (ARMS2) or complement factor H (CFH),
were significant in the non-white European populations
after correction for multiple testing, but this was likely
due to the small sample size used in this study [52].
However, Cheng et al. found a novel variant in the CETP
gene as well as novel AMD lipid/cholesterol genes asso-
ciated with AMD risk in East Asians [92]. Moreover, the
novel CETP risk variant was found to interact with high
serum HDL levels in individuals of Japanese ancestry
and Chinese from Singapore.
While GWAS and epidemiological studies have impli-
cated the lipid metabolism-cholesterol pathway in AMD
pathophysiology, the role is unclear and at times incon-
sistent [52, 53]. Given the variances within and among
ethnic populations with respect to AMD genetics, preva-
lence, and pathology, further effort needs to be focused
on working out the population-specific molecular
mechanisms that may influence individual patient re-
sponses to therapeutic interventions and progression of
the disease. To this end, transgenic and knockout animal
models have been created to model some of these genes
in vivo, including ABCA1, ABCA7, APOE, CETP, LIPC,
MMP9, and PLTP (Table 2) [93–103].
Epidemiology of cardiovascular health and AMD
Many recent studies have investigated the relationship be-
tween co-occurrences of AMD and cardiovascular-
associated conditions, often with apparently contradictory
findings (Table 3). An early paper by Kahn et al. in 1977
reported associations for AMD with systemic blood pres-
sure and with left ventricular hypertrophy by combining
data from participants in both the Framingham Heart
Study collected from 1948–1964 and the Framingham Eye
Study collected from 1973 to 1975 [104]. In the decades
that followed, data for associations between various AMD
phenotypes and a variety of cardiovascular-associated con-
ditions and factors have amassed through an assortment
of study designs. Age and tobacco smoking have been
well-established as risk factors for both cardiovascular
conditions and the development of AMD [105]. The
following sections will highlight the studies presenting
epidemiological associations among AMD phenotypes
and other cardiovascular risk factors. Complicating
factors in these studies include both the variety of
cardiovascular-associated and AMD phenotypes used
to represent risk or outcomes and the difficulty in
achieving robust AMD phenotypes.
Cardiovascular disease
AMD phenotypes have been variably associated with a
variety of CVD outcomes, including coronary heart dis-
ease (CHD)/CAD, myocardial infarction (MI), angina, or
a pooled composite cardiovascular disease category
[106]. Several studies have reported that they did not ob-
serve any association between AMD and cardiovascular
disease, including reports from the Eye Disease Case–
control Study Group [107], the Beaver Dam Eye Study
(BDES, [108, 109]), and a pooled data set from the
BDES, the Rotterdam Study, and the Blue Mountains
Eye Study (BMES, [110]), each of which comprised a
primarily white population. The 2004 evaluation of a
pooled data set of the BDES, the BMES, and Rotterdam
Study [111] focusing on incident GA, neovascular AMD,
or any late AMD observed various significant associa-
tions within individual study groups for association with
AMD, but observed no significant association for AMD
with history of MI in the pooled dataset. A number of
subsequent studies also reported no association between
AMD and CVD, including the Women’s Health Initiative
Sight Exam (WHISE) Ancillary Study [112], the Los
Angeles Latino Eye Study (LALES, [113]), a report on a
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CVD Kahn et al. 1977 [104], Hyman et al.
1983 [117], Tan et al. 2007 [118],
Fernandez et al. 2012 [124],
Wu et al. 2014 [125]
Delcourt et al. 2001 [129],
Nguyen-Khoa et al. 2008 [130]
Eye Disease Case–control Study
Group 1992 [107], Klein et al.
1993 [108], Smith et al. 2001
[110], Klein et al. 2003 [109],
Tomany et al. 2004 [111], Klein
et al. 2007 [112], Fraser-Bell et al.
2008 [113], Golan et al. 2011
[116], Erke et al. 2014 [115]
Cardiovascular mortality Clemons et al. 2004 [119],
Tan et al. 2008 [137]
MI Duan et al. 2007 [121],
Vassilev et al. 2015 [120]
Nguyen-Khoa et al. 2008 [130]
CHD Wong et al. 2007 [122],
Sun et al. 2009 [123], Fernandez
et al. 2012 [124], Wu et al. 2014
[125], Yang et al. 2014 [127]
Delcourt et al. 2001 [129]
CAD Thomas et al. 2015 [126],
Wang et al. 2015 [128]
Atherosclerosis van Leeuwen et al. 2003 [132],
Klein et al. 2007 [133],
Taniguchi et al. 2015 [134]
Klein et al. 2003 [131]
Stroke Tan et al. 2007 [118], Fraser-Bell
et al. 2008 [113], Tan et al. 2008
[137], Liao et al. 2008 [135],
Hu et al. 2010 [136], Wieberdink
et al. 2011 [138], Ikram et al. 2012
[139], Wu et al. 2014 [125]
Smith et al. 2001 [110], Delcourt
et al. 2001 [129], Klein et al. 2003
[109], Tomany et al. 2004 [111],
Klein et al. 2007 [112], Sun et al.
2009 [123], Erke et al. 2014 [115]
Hypertension Kahn et al. 1977 [104], Sperduto &
Hiller 1986 [144], Hyman et al. 2000
[145], Yang et al. 2014 [127],
Cheung et al. 2014 [148],
Thomas et al. 2015 [126]
Klein et al. 1993 [108], Smith et al.
2001 [110], Delcourt et al. 2001
[129], Klein et al. 2003 [131],
Tomany et al. 2004 [111], Tan
et al. 2007 [118], Fraser-Bell et al.
2008 [113], Yip et al. 2015 [147]
Diastolic blood pressure Vidaurri et al. 1984 [143],
Hyman et al. 2000 [145],
Fraser-Bell et al. 2008 [113]
van Leeuwen et al. 2003 [132]
Systolic blood pressure Klein et al. 2003 [109], van Leeuwen
et al. 2003 [132], Erke et al. 2014 [115]
Pulse pressure Klein et al. 2003 [109], van Leeuwen
et al. 2003 [132], Fraser-Bell et al. 2008
[113], Cougnard-Grégoire et al.
2013 [146]
Fraser-Bell et al. 2008 [113]
Total serum cholesterol Eye Disease Case–control Study
Group 1992 [107], Tomany et al.
2004 [111], Ulaş et al. 2013 [149]
Klein et al. 1993 [108],
Klein et al. 2003 [131], Tomany
et al. 2004 [111], Cheung et al.
2014 [148]
Smith et al. 2001 [110], Delcourt
et al. 2001 [129], Abalain et al.
2002 [151], Tan et al. 2007 [118],
Munch et al. 2013 [153], Erke et al.
2014 [115], Mulero et al. 2014 [152],
Klein et al. 2014 [53], Cheung et al.
2014 [148]
HDL-C Klein et al. 1993 [108], Delcourt et al.
2001 [129], Klein et al. 2003 [109],
Tomany et al. 2004 [111], Tan et al.
2007 [118], Cougnard-Grégoire
et al. 2014 [150]
Smith et al. 2001 [110], Abalain et al.
2002 [151], Tan et al. 2007 [118],
Erke et al. 2014 [115], Mulero et al.
2014 [152], Klein et al. 2014 [53],
Cheung et al. 2014 [148]
LDL-C Ulaş et al. 2013 [149] Abalain et al. 2002 [151], Tan et al.
2007 [118], Erke et al. 2014 [115],
Mulero et al. 2014 [152], Cheung
et al. 2014 [148]
Cholesterol intake Hyman et al. 2000 [145],
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Table 3 Epidemiological studies investigating associations between AMD and cardiovascular/lipid conditions (Continued)
HDL Hyman et al. 2000 [145],
Yip et al. 2015 [147]
Munch et al. 2013 [153]
LDL Munch et al. 2013 [153]
Total cholesterol/HDL-C ratio Tan et al. 2007 [118] Klein et al. 1993 [108] Tan et al. 2007 [118], Klein
et al. 2014 [53]
Hyperlipidemia Vassilev et al. 2015 [120]
Triglycerides Munch et al. 2013 [153] Delcourt et al. 2001 [129], Abalain
et al. 2002 [151], Tan et al. 2007
[118], Munch et al. 2013 [153],
Erke et al. 2014 [115], Mulero et al.
2014 [152], Yip et al. 2015 [147]
Phospholipids Abalain et al. 2002 [151]
BMI Klein et al. 2007 [112],
Delcourt et al. 2001 [129],
Ulaş et al. 2013 [149],
Erke et al. 2014 [115]
Klein et al. 2003 [109],
Klein et al. 2007 [112],
Smith et al. 2001 [110], Tomany
et al. 2004 [111], DeAngelis et al.
2004 [154], Tan et al. 2007 [118],
Munch et al. 2013 [153], Cheung
et al. 2014 [148]
Physical exercise Klein et al. 2003 [109],
Munch et al. 2013 [153],
Erke et al. 2014 [115]
Waist circumference Munch et al. 2013 [153] Erke et al. 2014 [115]
Waist-to-hip ratio Erke et al. 2014 [115]
Serum carotenoid levels Eye Disease Case–control
Study Group 1992 [107]
Dietary lutein/zeazanthin SanGiovanni 2007 [160],
SanGiovanni et al. 2008
[161], Bonds et al. 2014
[163], Chew et al. 2014
[164], Wu et al. 2015 [162]
Dietary DHA/EPA SanGiovanni 2007 [160],
SanGiovanni et al. 2008
[161], Wu et al. 2015 [162]
Statin use Klein et al. 2003 [173] Hall et al. 2001 [165], McCarty
et al. 2001 [166], Wilson et al.
2004 [167], McGwin et al.
2005 [168], Guymer at al.
2008 [175], Guymer et al.
2013 [176], Sasaki et al.
2013 [177], Ma et al. 2015
[174], Vavvas et al. 2016 [180]
Klein et al. 2007 [112], Cougnard-
Grégoire et al. 2013 [146], McGwin
et al. 2006 [170], Maguire et al.
2009 [171], Shalev et al. 2011
[114], Klein et al. 2014 [53],
Al-Holou et al. 2015 [172]
Female Sex Smith et al. 1997 [191],
Rudnicka et al. 2012 [192]
Hirvelä et al. 1996 [189], AREDS
Group 2000 [185], Buch et al. 2005
[184], Roh et al. 2008 [186], Laitinen
et al. 2010 [183], Fong & Contreras
2010 [188], Chakravarthy et al.
2010 [190], You et al. 2012 [187]
Hormone therapy Eye Disease Case–control
Study Group 1992 [107],
van Leeuwen et al. 2004 [194]
Smith et al. 2001 [110], Tomany
et al. 2004 [111]
Age at menarche Snow et al. 2002 [182]
Age at menopause Tomany et al. 2004 [111]
Time from menarche to menopause Tomany et al. 2004 [111]
CVD = cardiovascular disease; MI = myocardial infarction, CHD = coronary heart disease; CAD = coronary artery disease; HDL-C = high-density lipoprotein choles-
terol; LDL-C = low-density lipoprotein cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; BMI = body-mass index; DHA = docosahexaenoic
acid; EPA = eicosapentaenoic acid
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group of enrollees in a health maintenance organization
in Israel [114], and the Tromsø Study [115].
However, several other studies have reported signifi-
cant associations between AMD and CVD, representing
associations between a variety of AMD subtypes/symp-
toms and cardiovascular outcomes for a variety of eth-
nic populations. Hyman et al. [116] and the BMES
[117] reported significant associations between AMD
and a history of CVD. The AREDS [118] and another
BMES [119] found advanced AMD to associate with in-
creased cardiovascular deaths, while the BMES (2008)
also found early AMD to associate with increased CVD
mortality.
Duan et al. [120] and Vassilev et al. [119] reported that
AMD significantly associated with increased risk of myo-
cardial infarction (MI). The Atherosclerosis Risk in Com-
munities Study (ARCS, [121]) observed a significant
association between late AMD and incident CHD in a
population at high risk for CHD. However, in the Cardio-
vascular Health Study [122] comprised of a cohort of
white Americans and African Americans, early AMD but
not late AMD was associated with an increased risk of
CHD. The baseline presence of AMD did not predict oc-
currence of CHD or CVD in the Multi-Ethnic Study of
Atherosclerosis (MESA, [123]) full population, but late
AMD did associate with both CVD and CHD in a sub-
group comprised of older (65+) white participants. In a
meta-analysis published in 2014 of eight prospective and
five retrospective studies, Wu et al. [124] reported that
patients with early AMD had an increased risk for
CVD and for CHD. When they narrowed the analysis
to include only the prospective studies, they also ob-
served that subjects with late AMD had an increased
risk for CVD. Thomas et al. [125] reported significant
associations between AMD and CAD for individuals
over 75 years old in a U.S. Veterans’ Affairs primarily
male population.
Yang et al. [126] reported that rural Chinese subjects
with CHD had increased risk of early AMD. Wang et al.
[127] found that men with obstructive coronary stenosis
are more likely to have early AMD and showed a correl-
ation between the extent and severity of CAD and the
prevalence of AMD.
In fact, other studies have reported inverse associa-
tions between AMD and cardiovascular outcomes, sug-
gesting a protective effect, including data from the
Pathologies Oculaires Liées à l’Age (POLA) Study [128]
in which soft drusen were inversely associated with
CHD, angioplasty, and any type of CVD. Also, Nguyen-
Khao et al. [129] reported lower incidences of both MI
and cerebrovascular accidents among patients with neo-
vascular AMD compared to controls.
Continuation of the ongoing work on the processes
underlying each of these conditions is critical to fully
understanding the common biological factors predispos-
ing individuals to each of these conditions and to allow
for a more streamlined approach to managing diseases
of older age.
Atherosclerosis
Even with the apparent similarities between drusen and
atherosclerotic plaques, associations for AMD with ath-
erosclerosis are also inconsistent. Klein et al. observed
no significant association between early AMD and
common carotid artery plaques in a biracial U.S. popu-
lation in the Cardiovascular Health Study reported in
2003 [130]. However, also in 2003, van Leeuwen et al.
reported significant associations for AMD with having
4–6 plaques in the carotid artery and also with having a
high composite score of atherosclerosis in the prospect-
ive Rotterdam Study [131]. Further, early AMD associ-
ated with echolucent carotid artery plaque in the full
MESA study [132] cohort with other subclinical CVD
factors having variable associations among the various
ethnic subgroups. In addition, Taniguchi et al. [133] re-
ported in 2015 that neovascular AMD associated with
atherosclerosis.
The majority of these studies suggest a significant as-
sociation between the presence of atherosclerotic pla-
ques and the occurrence of AMD. This relationship is
certainly complex and not likely to be a simple cause-
and-effect scenario, but as researchers elucidate more of
the molecular mechanisms contributing to each of these
conditions, the precise details of their relationship will
certainly emerge.
Stroke
Many groups have reported data on the associations be-
tween stroke and AMD phenotypes, which have also pre-
sented conflicting data. Several studies have found no
significant associations between AMD and stroke, includ-
ing each of the following: the POLA Study [128]; pooled
data from the BDES, the Rotterdam Study, and the BMES
[110, 111]; the BDES [109] only; the WHISE Ancillary
Study [112]; the Cardiovascular Health Study [122]; and
the Tromsø Study [115].
However, several other papers have reported signifi-
cant associations between AMD phenotypes and stroke.
The LALES [113] reported that history of stroke or tran-
sient ischemic attack was associated with GA. Liao et al.
[134] observed 2-year incident stroke cases in a cohort
of 1.3 million Medicare enrollees with no major CVD at
baseline, and observed significant associations between
any AMD, neovascular AMD, and non-neovascular
AMD with incident stroke, including both ischemic and
hemorrhagic stroke. In a meta-analysis of eight prospect-
ive and five retrospective studies, Wu et al. [124] re-
ported that subjects with late AMD had an increased
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risk for stroke. In 2012, Hu et al. [135] observed the 5
year incidence of stroke in a group of Taiwanese patients
who received treatment for AMD, and observed an in-
creased risk of stroke during the five-year follow-up
period in patients with neovascular AMD compared to
controls. Tan et al. [117] reported on the 10-year inci-
dence of AMD associated with stroke from the BMES
and observed significant associations for early but not
late AMD, with a history of stroke. Later, Tan et al.
[136] reported additional data from the BMES in
which they found that among patients <75 years old
at baseline, but not for patients 75+ years old at base-
line, there was a tenfold increase in stroke mortality
for patients with late AMD compared to controls
without AMD. Wieberdink et al. [137] found that late
AMD was significantly associated with an increased
risk of any stroke and of intracerebral hemorrhage,
but was not significantly associated with risk of cere-
bral infarction in the Rotterdam study. The ARCS
[138] reported that subjects with either any or early
AMD had increased risk of stroke, including both
cerebral infarction and intracerebral hemorrhage.
As for the phenotypes discussed above, the specific
stroke diagnostic phenotypes varied from study to study,
which complicates the interpretation of the associations
found between them and the various AMD phenotypes.
However, the recurrence of such associations across
studies suggests a relationship between the two condi-
tions, thereby warranting closer inspection.
Hypertension
Systemic hypertension has been shown to associate
with decreased choroidal blood flow, which in turn is
associated with the development of AMD, further sug-
gesting that AMD development and/or progression
have systemic contributions [139–141]. A number of
studies have found significant associations between
AMD phenotypes and blood pressure measures. As
early as 1977, Kahn et al. reported associations between
AMD and systemic blood pressure in data from the
Framingham Eye Study [104]. Vidaurri et al. [142] re-
ported an association between drusen and diastolic blood
pressure in a Jewish population. In 1986, Sperduto &
Hiller [143] reported a significant association between
incidence of AMD and duration of hypertension, with
longer duration of hypertension associated with higher
risk of AMD. In 2000, Hyman et al. [144] reported sig-
nificant associations for neovascular AMD with high
diastolic blood pressure and hypertension in the AMD
Risk Factors Study Group. The BDES [109] observed
significant associations of higher systolic blood pressure
with RPE depigmentation and neovascular AMD as well
as higher pulse pressure with RPE depigmentation, retinal
hyperpigmentation, neovascular AMD, and progression
of AMD. Cougnard-Grégoire et al. [145] reported a
significant association between elevated pulse pressure
and risk of late AMD in the Antioxydants, Lipids
Essentiels, Nutrition et maladies OculaiRes (ALIENOR)
study in a French population. Yang et al. [126] reported
that rural Chinese subjects with untreated hypertension
had increased risk of early AMD. Thomas et al. [125]
reported significant associations between AMD and
hypertension in a U.S. Veterans’ Affairs primarily male
population.
Other studies have not observed significant associations
between AMD and blood pressure, including the BDES
[108], the POLA study [128], a pooled BDES, BMES, and
Rotterdam Study [110, 111], the Cardiovascular Health
Study [130], the BMES alone [117], and the European Pro-
spective Investigation Into Cancer (EPIC) Norfolk Eye
Study [146].
A few papers reported inconsistent associations for
different blood pressure measurements. The Rotterdam
Study [131] observed significant associations for AMD
with increased systolic blood pressure and increased
pulse pressure, but no significant associations were
found for diastolic blood pressure. In the LALES [113],
no significant associations with AMD were observed for
a history of hypertension, but significant associations
were reported as follows: increased diastolic blood pres-
sure associated with neovascular AMD; increased pulse
pressure associated with RPE depigmentation and was
protective for GA; and moderate pulse pressure was pro-
tective for neovascular AMD. Later, the Tromsø Study
[115] showed significant associations for risk of late
AMD with increased systolic blood pressure in women,
but not in men. Cheung et al. [147] evaluated a multi-
ethnic Asian population comprised of Chinese, Malay,
and Indian subjects living in Singapore and reported a
significant positive association for risk of early but not
late AMD with hypertension.
As for the other cardiovascular-associated pheno-
types, blood pressure measures are variably reported
in these studies. Likewise, hypertension status can
vary over an individual’s lifespan, thus confounding
the relationship between measurements of blood pres-
sure and AMD status.
Lipid levels- triglycerides, cholesterol (HDL, LDL, total),
phospholipids
The Eye Disease Case–control Study Group consortium
[107] reported in 1992 that an increased risk of neovas-
cular AMD was significantly associated with higher
serum cholesterol levels. Similar to the other cardiovas-
cular conditions, later studies showed mixed results re-
garding the association of serum cholesterol and
triglyceride levels with AMD.
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A large number of studies have shown significant asso-
ciations between AMD and serum lipid levels. The
AMD Risk Factors Study Group [144] observed a signifi-
cant association for neovascular AMD with dietary in-
take of cholesterol and with high HDL levels. The
biracial Cardiovascular Health Study [130] observed a
significant association between early AMD and lower
serum total cholesterol. The BDES (2013) reported a sig-
nificant association between higher serum HDL- choles-
terol (HDL-C) and pure geographic atrophy [109]. A
pooled data set of the BDES, the BMES, and Rotterdam
Study (Tomany et al. [111]) found significant lipid asso-
ciations between total serum cholesterol levels positively
associated with incident GA and inversely associated
with incident neovascular AMD in the combined data-
set. Ulaş et al. [148] reported that total cholesterol and
LDL-C were significantly associated with neovascular
AMD. The ALIENOR study [149] reported a significant
association between elevated HDL-C levels and early or
any AMD. Furthermore, Vassilev et al. [119] reported an
increased risk of AMD for patients with hyperlipidemia.
Several other studies failed to show a significant asso-
ciation between AMD and serum lipid levels. Pooled
data from the BDES, the BMES, and the Rotterdam
Study [110] showed no significant associations with
cholesterol or HDL-C. Abalain et al. [150] reported in
2002 on associations of AMD with serum lipids in a
French cohort, and they observed no significant
associations for AMD with cholesterol, triglycerides,
phospholipids, HDL-C, or LDL-C. Data from the
Tromsø Study [115] showed no significant association
for late AMD with total cholesterol, LDL-C, HDL-C, or
triglycerides. Mulero et al. [151] reported no significant
association between neovascular AMD and total choles-
terol, triglycerides, HDL-C, or LDL-C.
Yet, other studies reported variable associations among
serum lipid levels and AMD. The BDES [108] found that
in women, AMD related to low total serum cholesterol
levels, but that in men, AMD was associated with both
high HDL-C levels and a low total cholesterol/HDL-C
ratio. The POLA Study [128] found that soft drusen
were positively associated with HDL-C, but observed no
significant association between AMD and total choles-
terol or triglycerides. The BMES [117] observed signifi-
cant associations for late AMD with HDL-C and the
ratio of total cholesterol/HDL-C; but for early AMD,
they observed no significant associations with HDL-C,
LDL-C, triglycerides, total cholesterol, or the ratio of
total cholesterol/HDL-C. Munch et al. [152] also ob-
served an increased risk for moderate to large macular
drusen in women with elevated levels of serum triglycer-
ides, but no association was observed between moderate
to large macular drusen and serum triglyceride levels in
men. Triglyceride levels were also significantly associated
in this study with the presence of 20+ small, hard macu-
lar drusen in both men and women with moderately
elevated triglyceride levels, but not for subjects with
the highest triglyceride levels. They further observed a
significant increased risk for 20+ small, hard drusen
for subjects in the second to lowest of five LDL levels
compared to the lowest LDL level. They did not ob-
serve any associations between risk for 20+ small,
hard drusen and HDL levels or total cholesterol.
A meta-analysis of data from the BDES, BMES, and
the Rotterdam Study (2014) did not observe signifi-
cant associations between any of these measures
and AMD outcomes in their combined analysis [53].
Cheung et al. [147] evaluated a multiethnic Asian
population comprised of Chinese, Malay, and Indian
subjects living in Singapore in which they observed a
significant inverse association for risk of early AMD
with total cholesterol. They did not observe any sig-
nificant associations for late AMD with total choles-
terol, LDL-C, or HDL-C. Yip et al. [146] observed a
significant association between higher HDL levels
and development of AMD in the EPIC Norfolk Eye
Study, but found no association of AMD with serum
triglyceride levels.
The underlying factors contributing to the observed
associations or the lack of association between AMD
phenotypes and lipid levels among various populations
requires further investigation to understand their true
relationships. Understanding the contributions of lipid
factors to the development and progression of AMD will
provide insight into the mechanisms of AMD pathology
with the potential for presenting intervention options
for the management of the disease.
Obesity, BMI, & physical activity
Several studies have looked at the relationships among
AMD-associated phenotypes and weight and physical ac-
tivity. As for the data presented above for the other car-
diovascular risk factors, reports on associations between
AMD and weight/activity measures have also been
mixed. The POLA Study [128], the WHISE Ancillary
Study [112], and Ulaş et al. [148] reported significant as-
sociations for high BMI with increased risk for late
AMD. The Cardiovascular Health Study [130] and the
WHISE Ancillary Study [112] also found significant as-
sociations between lower BMI and incidence of GA. Fur-
ther, the Cardiovascular Health Study [130] reported a
significant protective association between physical exer-
cise and the incidence of GA, neovascular AMD, and
progression of AMD.
Alternatively, other studies were unable to identify sig-
nificant associations for BMI with AMD. These include
pooled data from the BDES, the Rotterdam Study, and
the BMES [110, 111], BMES-only data [117], and a
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multiethnic Asian population comprised of Chinese,
Malay, and Indian subjects living in Singapore [147], all
of which reported no significant associations with BMI.
DeAngelis et al. [153] reported data from extremely dis-
cordant sib pairs that were suggestive, but not signifi-
cant, for association of BMI with neovascular AMD.
The results of other studies have presented mixed re-
sults, with differences arising between the sexes. The In-
ter99 Eye Study [152] reported a lower risk of moderate
to large macular drusen associated with higher levels of
physical activity for both men and women, but a differ-
ential association between waist circumference and risk
for AMD that was differentiated by sex. In men, the like-
lihood of moderate to large macular drusen increased
with increasing waist circumference, but for women, the
likelihood of moderate to large macular drusen was
higher for each the bottom and top quartiles of waist cir-
cumference. These authors did not observe any signifi-
cant association between moderate to large macular
drusen and BMI. Also, the Tromsø Study [115] found
significant associations for risk of late AMD with high
BMIs for women and a protective effect of exercise for
women. However, these authors observed no significant
associations for late AMD with waist circumference or
waist-to-hip ratio in women and no significant associa-
tions were reported for any of the aforementioned fac-
tors for men.
Further studies are needed to work out the relation-
ship of weight and activity factors with AMD, particu-
larly given that weight and activity are both modifiable
traits. This presents one difficulty in interpreting rela-
tionships between weight/activity measures and disease
state in that these traits may vary substantially through-
out an individual’s lifespan. However, if proven to be
contributing elements to the development and/or pro-
gression of AMD, these factors would present interven-
tional opportunities to help prevent or slow disease
incidence or progression.
Antioxidant and other supplement use
Oxidative stress has been associated with the develop-
ment and progression of both AMD and CVD (reviewed
in [154–157]). Antioxidants, including the long-chain
omega-3 fatty acids, docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA), and the macular xantho-
phylls (MXs) lutein and zeaxanthin have been investi-
gated for their potential roles in preventing the
progression of AMD. Lutein and zeaxanthin are essential
nutrients found in high quantities in the human retina
[158]. In 1992, the Eye Disease Case–control Study
Group consortium [107] reported a decreased risk for
neovascular AMD significantly associated with higher
levels of serum carotenoids (including lutein and zea-
xanthin) in a U.S. population. This finding has been
replicated by several studies, including the AREDS [159,
160] and the Nurses’ Health Study/ Heath Professionals
Follow-up Study [161] which found inverse associations for
dietary lutein/zeaxanthin and dietary DHA/EPA with AMD.
The follow-up to the AREDS, AREDS2 [162], was a double-
masked, randomized, controlled trial of nutritional supple-
mentation looking at the effects on AMD progression, which
found a significant effect of supplementation with lutein and
zeaxanthin to reduce progression to neovascular AMD [162,
163]. However, the AREDS2 [162] also looked at the effects
of lutein/zeaxanthin and DHA/EPA supplementation on
CVD outcomes and reported no significant effect. The im-
portant role of MXs in this disease suggests a more com-
plicated role for HDL in AMD than simply acting as a
cholesterol carrier.
Statin use
Hall et al. [164] initially reported a protective effect of
statin (HMG-CoA reductase inhibitor) use on AMD in
2001, which was followed shortly by a report from
McCarty et al. [165] similarly showing a protective effect
of statin use. Likewise, Wilson et al. [166] showed in
2004 a significant retrospective association for statin use
with decreased rates of CNV, and McGwin et al. [167]
showed in 2005 a significant prospective association
for cholesterol-lowering drug use and decreased risk
of AMD. Guymer et al. [168] reviewed the various
functions of statins in reducing atherosclerotic disease
and proposed that such functions may also benefit
AMD development, including the lipid-lowering, anti-
inflammatory, and anti-angiogenic effects of statins.
Specifically, they suggest that the statin-induced in-
hibition of high sensitivity C reactive protein and
VEGFA expression may potentially contribute to re-
duced progression of AMD.
However, subsequent reports on associations for
AMD and statin use have been predominantly nega-
tive for association. The Cardiovascular Health Study
[169], the WHISE Ancillary Study [112], the Compli-
cations of Age-related Macular Degeneration Preven-
tion Trial (CAPT) study [170], Shalev et al. [171], an
ALIENOR study [145], and the AREDS2 [172] all ob-
served no significant associations between AMD and
statin use. A BDES report [173] indicated no signifi-
cant association between statin use and AMD overall,
but did report a significant association between those
who started taking statins during the course of the
BDES and the presence of large drusen or late AMD,
although this association may have resulted from dif-
ferences at baseline between those who initiated sta-
tins and those who did not. A meta-analysis of data
from the BDES, the BMES, and the Rotterdam Study
[53] observed significant associations between statin
use with AMD outcomes within individual study
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groups; however, they did not observe significant associa-
tions between statin use and AMD outcomes in their
meta-analysis. A meta-analysis [174] published in 2015 in-
cluding 14 previously reported studies observed no signifi-
cant association between statin use and any AMD.
However, they did observe significant protective effects for
statin use on both early AMD and neovascular AMD, but
not for geographic atrophy.
The Age-Related Maculopathy Statin Study (ARMSS)
reported in 2013 on a 3-year randomized, placebo-
controlled double masked trial of simvastatin in an
AMD population at high risk of progression to advanced
disease [175–177]. They observed a reduction in the risk
of progression of AMD with simvastatin treatment com-
pared to placebo, as well as an increase in the retinal
vascular caliber with treatment, both indicating a pro-
tective effect of statin use on AMD development. Pa-
tients with advanced AMD in one eye had no benefit of
treatment on the risk of progression of the fellow eye to
advanced disease. However, patients with bilateral inter-
mediate AMD at baseline had a 77% reduction in risk of
progression to advanced AMD compared to the placebo
group. The authors also identified an interaction be-
tween response to simvastatin treatment and the Y402H
risk allele of CFH such that patients homozygous for the
C risk allele had a 12-fold reduction in AMD progres-
sion with simvastatin over patients with the heterozy-
gous CT or homozygous TT alleles who also received
simvastatin treatment. This study provides a strong justi-
fication for further investigation of statin use for the pre-
vention of AMD progression, particularly in patients
with intermediate bilateral AMD and/or those with the
CHF Y402H CC risk genotype.
However, Gehlbach et al. [178] recently published a re-
view of statin use for age-related macular degeneration
in which they evaluated and compared the two random
controlled trials of simvastatin for AMD to date (Guy-
mer et al. [176] and Martini et al. [179]) and concluded
that the current evidence is insufficient for the treatment
of AMD with statins due to problems associated with
each study. The Martini et al. trial was small and short
(30 participants for three months), which was insuffi-
cient to properly evaluate either beneficial or adverse
outcomes for this slowly progressing disease. Although
the Guymer et al. study included 144 participants, only
70% of the participants completed the full 3-year follow-
up.
Recently, Vavvas et al. [180] presented a case report in
which a patient with dry AMD had regression of drusen
following high-dose statin administration. This finding
was followed up by a prospective, non-randomized inter-
ventional study in which 23 patients with early AMD
and at high risk for disease progression were given high
dose statin (80 mg atorvastatin) daily for up to 1.5 years.
10 of these patients experienced regression of drusen,
and none of the patients progressed to advanced stage
disease. This study included a narrowly defined risk
group comprised entirely of Caucasian White U.S. and
European patients who received a standard dose of a
single statin. The authors propose that the heterogeneity
within the study populations used to identify associa-
tions between statin use and AMD may account for the
inconsistency of associations among prior studies. It
would be interesting to see if a negative association for
statin use with AMD progression or occurrence would
be significant in existing data sets were they to be re-
stricted to high risk individuals with early AMD who
have taken high dose atorvastatin for 1 to 1.5 years. Fur-
ther work with randomized, controlled interventional
studies will be useful for working out the details and the
extent to which this study can be extrapolated to pa-
tients that do not conform to the specific phenotypic
and ethnic categories from which these study partici-
pants were drawn.
Certainly, more information is needed on the risks or
preventive effects of statins, which are commonly being
taken by aging patients. A better understanding of the
relationship between these drugs and the development
of AMD will improve the management of both cardio-
vascular disease and AMD. Further, any drugs that may
prove to have a beneficial effect on AMD outcomes
should be considered for their possible use as a thera-
peutic for the treatment of AMD.
Sex
According to the National Eye Institute, 65% of preva-
lent AMD cases in 2010 were female patients [181]. One
explanation for the higher prevalence of AMD among
women is the longer life expectancy of women compared
to men, which makes them more likely to acquire age-
dependent diseases. This may not fully explain the sex
differences observed for AMD, as some studies show dif-
ferential risk associations for AMD among women com-
pared to men. Further support for distinctions between
the disease processes in men and women arise from the
observations that the use of hormone therapies (HTs)
have a protective effect against the development of
AMD in women [182].
Epidemiological data has been mixed regarding the
sex-associated risk of AMD. Many studies analyzing the
sex-specific risk of AMD have not found significant as-
sociations between AMD and sex [183–190]. Other
studies have shown differential disease risks for men and
women [191, 192]. Munch et al. [152] reported in 2013
that they found a differential association between waist
circumference and risk for AMD by sex. In 2014, Yang
et al. [126] reported that, after adjusting for age and
smoking status, men had a significantly increased risk of
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large drusen, but not early AMD and other specific le-
sions, suggesting a potential difference in disease path-
ology for men compared to women. Erke et al. reported
on data from the Tromsø Study [115] in which they
found significant associations for risk of late AMD with
BMI, systolic blood pressure, and exercise only for
women. A 2015 paper by Wang et al. [127] reported on
a study group comprised of patients who presented to
the hospital for assessment of suspected CAD, which
was comprised of 76% men, in which they found risk for
early AMD to be associated with cardiovascular risk fac-
tors differently for males than females.
Other studies have suggested a protective effect of es-
trogen on AMD development and/or progression. Snow
et al. [182] observed an increased risk for AMD with
older age at menarche [185]. Tomany et al. [111] evalu-
ated a pooled data set of the BDES, the BMES, and Rot-
terdam Study and observed a significant association for
older age at menopause with geographic atrophy in the
BMES and a longer time between menarche and meno-
pause associated with increased rates of GA in the
Rotterdam Study. However, when the data from the
three studies were pooled together, no significant as-
sociations between incident late AMD and age at
menopause, time from menarche to menopause, or
hysterectomy-induced menopause remained.
Current data also suggests a connection between
AMD and the use of HT. Estrogen has antioxidant
properties, which have been proposed to contribute to
a protective role for AMD along with potential effects
via the anti-inflammatory or other regulatory functions
of estrogen [193]. Studies which identify a significant
association between the use of HT and AMD suggest
that these drugs may have a protective effect. In 1992,
The Eye Disease Case–control Study Group consortium
[107] reported a decreased risk for neovascular AMD
significantly associated with the use of postmenopausal
exogenous estrogens in a U.S. population. Later, both
Smith et al. [110] in 2001 and Tomany et al. [111] in
2004 reported on pooled data from the BDES, BMES,
and the Rotterdam Study where they observed no sig-
nificant associations for incident late AMD with ever
use of HT. However, van Leeuwen et al. [194] also ana-
lyzed a pooled dataset of information from the BDES,
BMES, and the Rotterdam Study (2004) in which they
observed a decreased risk of early AMD with use of HT
in the pooled population. Note that this pooled analysis of
the BDES, BMES, and Rotterdam Studies was performed
contemporaneously with the pooled analysis by Tomany
et al. [111]. However, the van Leeuwen analysis focused
on incident early AMD in which participants with any
AMD at baseline were excluded, whereas Tomany et al.
evaluated incident GA, neovascular AMD, and combined
late AMD regardless of the presence of AMD at baseline.
Cardiovascular disease is known to present differently
in women compared to men, and the efficacy and side
effects of treatments such as aspirin and statins may also
vary by sex [195]. Estrogens may reduce the develop-
ment of atherosclerotic plaques, but may also contribute
to destabilizing existing plaques, thereby increasing car-
diovascular events in the short term, but reducing these
events in the long run [196–198]. Combining statin use
with HT appears to prevent the estrogen-induced ath-
erosclerotic plaque instability [199]. Combination statin/
HT has also been observed to significantly decrease the
risk of all-cause mortality (which was driven mainly by
cardiovascular mortality) over statin-only treatment for
primary prevention of cardiovascular events [200]. It will
be interesting to determine whether a combined treat-
ment plan including both a statin and HT would provide
added benefit for the prevention of AMD progression.
The sex differences apparent for both AMD and CVD
require that future studies are designed to maximize in-
formation for both sexes to fully understand both the
commonalities and the differences underlying each of
these diseases in both male and female patients. Along
with considerations of genetic and environmental fac-
tors, sex needs to be considered in the design of person-
alized treatment regiments that optimize individual
therapeutic responses. The recent NIH requirement to
treat sex as a biological variable (see NIH notice NOT-
OD-15-102 and related announcements) will improve
reporting of data on sex-specific findings and further un-
derstanding of the sex differences inherent in this com-
plex, heterogeneous disease. Even without individual
studies being powered to detect sex differences, the
availability of the data will allow for future meta-analysis
to extract sex-specific findings.
Conclusions
Given the complex and heterogeneous nature of both
cardiovascular conditions and AMD, it would stand to
reason that not all contributions to disease would be
common to both conditions. For example, some genes
associated with AMD [e.g., complement factor I (CFI),
TNF receptor superfamily member 10a (TNFRSF10A),
beta 1,3-galactosyltransferase-like (B3GALTL), and solute
carrier family 16 member 8 (SLC16A8)] have not to date
been associated with CVD [24, 201]. However, given
both the extent of epidemiological data, for both gen-
etic and environmental factors, linking the diseases and
the known molecular commonalities, there appears to
be substantial overlap among the factors contributing
to each condition. Understanding the relationship be-
tween AMD and CVD will certainly prove to be a sig-
nificant advancement in our understanding of AMD,
allowing the relatively young AMD field to benefit from
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prior and ongoing advances in the more mature cardio-
vascular field.
Clarifying the molecular, physiological, and patho-
logical roles in AMD development and progression of
each of the factors presented herein is necessary for a
complete understanding of this blinding disease. Insights
into the underlying molecular influences, including epi-
genetic influences (such as DNA methylation or histone
modifications), on disease progression will also contrib-
ute to the development of improved therapeutic inter-
ventions. Not only do clinicians and scientists need to
understand the various contributions of each factor, but
understanding the interactions among risk/protective
factors will also be essential to developing precision
medicine in the clinical environment. A 2011 paper by
Feehan et al. [202] divided neovascular AMD patients
into four subtypes by both genetic and cardiovascular
risk factors. In this analysis, the patients clustered based
on blood pressure, hypercholesterolemia, BMI, and ge-
notypes at the HTRA1 and CFH loci. Each cluster was
defined by phenotype/genotype combinations, which il-
lustrates the importance of looking across risk factors to
understand each patient’s disease status and to design
appropriate interventions. This study also underscores
why many therapeutics fail during clinical trials, as they
do not take both genotype and risk factor phenotypes
into account simultaneously when examining disease
outcome.
The epidemiological data presented herein must be
validated clinically with randomized, double blind, pro-
spective, interventional, controlled trials and biologic-
ally with molecular, cellular, and physiological studies
in the laboratory to understand the complex patho-
physiology and molecular mechanisms underlying the
disease process. Such studies are critical for taking
current understanding beyond observing disease associ-
ations to determining cause and effect relationships
underlying disease, which will allow for targeted thera-
peutic intervention accordingly. Such interventions are
crucial for improving the quality of life for millions of
patients worldwide.
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